HVO Hvivo Plc

TIDMRVG

RNS Number : 1590P

Retroscreen Virology Group PLC

22 October 2012

For immediate release 07.00: 22 October 2012

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

CONTRACT WIN

Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "Virometrics" specialist, is pleased to announce the signing of a Viral Challenge Model ("VCM") contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study. The contract, valued at GBP5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.

Kym Denny, Chief Executive Officer, commented, "We are delighted to be working with such an innovative pharmaceutical company on the development of their novel product. This contract win comes from the building momentum of Retroscreen's sales pipeline and highlights the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)

Graham Yeatman (FD)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTBKDDPOBDDDKB

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024